Clinical trials: Psoriatic Arthritis, active
Moderate to Severe Psoriatic Arthritis
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
The purpose of this 1-year open-label extension study is to characterize the longer-term safety and tolerability of DDY391 and to assess the durability of clinical response in participants with Psoriatic Arthritis (PsA) who have…
- Trial name
- NCT07923773
- Testing
- DDY391
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Meibomian Gland Dysfunction, Dry Eye Syndromes
Ocular Surface Changes and Meibomian Gland Dysfunction in Rheumatologic Patients
This observational study aims to assess the frequency and severity of Meibomian Gland Dysfunction (MGD) and associated ocular surface changes in patients with systemic autoimmune rheumatic diseases compared with healthy…
- Conditions
- Meibomian Gland Dysfunction, Dry Eye Syndromes, Rheumatoid Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT07810569
- Volunteers
- 150 people
- Sponsor
- Assiut University
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases
The goal of this clinical trial is to assess the effectiveness of a disease activity guided dose reduction strategy of Janus kinase inhibitor (JAKi) compared to disease activity guided JAKi continuation in patients with…
- Conditions
- Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Axial Spondyloarthritis (AxSpA)
- Trial name
- REDO-JAK (NCT07160231)
- Testing
- JAKi dose reduction strategy, JAKi disease activity guided continuation of same dose strategy
- Where
- 7 sites in Netherlands
- Volunteers
- 200 people
- Sponsor
- Sint Maartenskliniek
Active Moderate to Severe Rheumatoid Arthritis, Active Ankylosing Spondylitis
Korean Post-marketing Surveillance for Xeljanz XR
Xeljanz XR extended-release tablets 11 mg (Tofacitinib citrate) is a drug subject to the risk management plan in accordance with Article 4-1-11 of the "Regulation on Safety of Medicinal Products, etc." in Korea.
- Conditions
- Active Moderate to Severe Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis
- Trial name
- XRPMS (NCT04876781)
- Testing
- Tofacitinib XR
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Pfizer
Psoriatic Arthritis, Ultrasound Assessment
Apremilast and Adalimumab in Psoriatic Arthritis Patients
The aim of this work is to compare the efficacy of Apremilast combined with Methotrexate versus Adalimumab combined with Methotrexate
- Conditions
- Psoriatic Arthritis, Ultrasound Assessment, TNF
- Trial name
- NCT07398651
- Testing
- Adalimumab, Apremilast
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Juvenile Psoriatic Arthritis
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time.
- Trial name
- NCT06100744
- Testing
- Adalimumab, Risankizumab
- Where
- 34 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AbbVie
Crohn Disease, Ulcerative Colitis
Safety and Efficacy of Fecal Microbiota Transplantation
The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease…
- Conditions
- Crohn Disease, Ulcerative Colitis, Celiac Disease, Irritable Bowel Syndrome
- Trial name
- NCT04014413
- Testing
- Fecal Microbiota Transplantation
- Where
- Hong Kong
- Volunteers
- 450 people
- Sponsor
- Chinese University of Hong Kong
Arthritis, Psoriatic
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug
This is a study to demonstrate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult patients with active psoriatic arthritis who are naive to biologic…
- Trial name
- IZAR-1 (NCT06641076)
- Testing
- Sonelokimab
- Where
- 182 sites in United States, Bulgaria and 18 more
- Volunteers
- 960 people
- Sponsor
- MoonLake Immunotherapeutics AG
Psoriatic Arthritis (PsA)
Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis
This study will investigate if the study medicine FT2109 can treat symptoms of active Psoriatic Arthritis (PsA). This study assesses the safety and efficacy of FT2109 in adult participants with active PsA who may or may not have…
- Trial name
- NCT07869134
- Testing
- FT2109 Dosing Regimen 1, FT2109 Dosing Regimen 2
- Volunteers
- 210 people
- Sponsor
- Forward Therapeutics
Psoriatic Arthritis
Sex and Gender-based Analysis of the Effectiveness of Advanced Therapies in Psoriatic Arthritis
Sex and gender are important factors that influence treatment response in PsA. The goal of this multi-centre observational study is to understand how sex and gender influence response to advanced therapies in psoriatic arthritis…
- Trial name
- SAGE-PsA (NCT05954364)
- Where
- Canada
- Volunteers
- 540 people
- Sponsor
- Women's College Hospital
Psoriasis (PsO), Psoriatic Arthritis (PsA)
Physician- vs Questionnaire-Based Screening for Psoriatic Arthritis in Psoriasis
Early diagnosis of psoriatic arthritis (PsA) requires close collaboration between dermatologists (as the skin manifestations of psoriatic disease in most cases precede the musculoskeletal manifestations) and rheumatologists (who…
- Trial name
- COMPOSITION (NCT07298265)
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- Charite University, Berlin, Germany
Psoriatic Arthritis
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs.
- Trial name
- NCT04908202
- Testing
- Deucravacitinib
- Where
- 183 sites in United States, Argentina and 19 more
- Volunteers
- 670 people
- Sponsor
- Bristol-Myers Squibb
Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.
Ankylosing spondylitis, radiographically negative axial spondyloarthritis, psoriatic arthritis, polymyalgia rheumatica, Takayasu arteritis, giant cell arteritis, non-ocular Behcet's disease, and enthesitis-related arthritis are…
- Conditions
- Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Nr-axSpA, Polymyalgia Rheumatica (PMR)
- Trial name
- V-MIRACLE (NCT06766552)
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Plaque Psoriasis, Psoriatic Arthritis
Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)
Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy.
- Conditions
- Plaque Psoriasis, Psoriatic Arthritis, Scalp Psoriasis, Nail Psoriasis
- Trial name
- NCT06802848
- Testing
- Xeligekimab injection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chongqing Genrix Biopharmaceutical Co., Ltd
Psoriatic Arthritis, Spondyloarthritis
The Corrona Psoriatic Arthritis and Spondyloarthritis (PsA-SpA) Registry
This prospective, non-interventional, research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for PsA-SpA in a cohort of patients cared for by rheumatologists across…
- Trial name
- NCT02530268
- Volunteers
- 5,000 people
- Sponsor
- CorEvitas
Psoriatic Arthritis
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).
- Trial name
- KEEPsAKE 1 (NCT03675308)
- Testing
- Risankizumab
- Where
- 256 sites in United States, Argentina and 37 more
- Volunteers
- 964 people
- Sponsor
- AbbVie
Psoriatic Arthritis
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin. The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over…
- Trial name
- NCT07286058
- Testing
- Zasocitinib
- Where
- 78 sites in United States, Australia and 14 more
- Volunteers
- 1,182 people
- Sponsor
- Takeda
Psoriatic Arthritis, Enthesitis
Ultrasound and Shear Wave Elastography Assessment of Entheses in Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory disease that frequently involves the entheses, where tendons, ligaments, and fascia insert into bone.
- Trial name
- SWE-PsA (NCT07785089)
- Testing
- Grayscale Ultrasonography, Power Doppler Ultrasonography, and Shear Wave Elastography
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Marmara University
Inflammatory Arthritis, Spondylarthropathies
Assessing Pain by the painDETECT Questionnaire (PDQ)
Prospective cohort study using drug survival rates to assess the predictive value of the PDQ when used to classify patients into a non-neuropathic pain phenotype group (score <13) or a neuropathic pain phenotype group (score ≥13)
- Conditions
- Inflammatory Arthritis, Spondylarthropathies, Rheumatoid Arthritis, Psoriatic Arthritis
- Trial name
- NCT06402396
- Testing
- bDMARDS
- Volunteers
- 7,056 people
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Rheumatoid Arthritis, Psoriatic Arthritis
Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication
The purpose of this study is to assess the strength and duration of the immunological response to COVID-19 vaccines in patients treated with immunosuppressive and/or immunomodulating medication for immune-mediated inflammatory…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Spondyloarthritis, Crohn Disease
- Trial name
- Nor-vaC (NCT04798625)
- Where
- 2 sites in Norway
- Volunteers
- 2,300 people
- Sponsor
- Diakonhjemmet Hospital